In addition to traditional cardiovascular (CV) risk factors such as smoking, type 2 diabetes mellitus (T2DM), hypertension (HTN) and dyslipidemia, researchers have investigated potential novel biomarkers, for instance, copeptin1, pentraxin-32 and heart-type fatty acid binding protein (H-FABP) to predict the clinical course and CV outcomes. Here, FABP3 is linked to metabolic syndrome.